Markets:

Overview

News

Currencies

International

Treasuries

CG Oncology, Inc. - Common stock (NQ:CGON)

75.92 -1.19 (-1.54%)

Streaming Delayed Price Updated: 1:36 PM EDT, Aug 18, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about CG Oncology, Inc. - Common stock

< Previous 1 2 3 4 Next >

CG Oncology Reports Third Quarter 2024 Financial Results and Provides Business Updates

November 12, 2024

From CG Oncology Inc.

Via GlobeNewswire

CG Oncology Announces Nature Medicine Publication of Phase 1b Study Results Evaluating Cretostimogene Grenadenorepvec in Combination with Nivolumab in Muscle-Invasive Bladder Cancer

November 11, 2024

From CG Oncology Inc.

Via GlobeNewswire

Discover the 3 Best-Performing Biotech IPO Stocks of 2024

November 06, 2024

Check out which three biotechnology companies that went public in 2024 and are performing the best and a big factor influenced their rise.

Via MarketBeat

Topics Initial Public Offering

This Sempra Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Thursday ↗

October 24, 2024

Via Benzinga

A Closer Look at 9 Analyst Recommendations For CG Oncology ↗

June 28, 2024

Via Benzinga

Decoding 10 Analyst Evaluations For CG Oncology ↗

May 14, 2024

Via Benzinga

CG Oncology to Participate in the Morgan Stanley 22nd Annual Global Healthcare Conference

August 30, 2024

From CG Oncology Inc.

Via GlobeNewswire

CGON Stock Earnings: CG Oncology Beats EPS for Q2 2024 ↗

August 08, 2024

CGON stock results show that CG Oncology beat analyst estimates for earnings per share the second quarter of 2024.

Via InvestorPlace

CG Oncology Reports Second Quarter 2024 Financial Results and Provides Business Updates

August 08, 2024

From CG Oncology Inc.

Via GlobeNewswire

CG Oncology Initiates Expanded Access Program for Cretostimogene Grenadenorepvec

June 18, 2024

- First Patient Dosed in Expanded Access Program and Enrollment Ongoing -

From CG Oncology Inc.

Via GlobeNewswire

CG Oncology Announces Nature Medicine Publication of Final Results from CORE-001 Study of Cretostimogene Grenadenorepvec in Combination with Pembrolizumab in BCG-Unresponsive NMIBC

June 06, 2024

From CG Oncology Inc.

Via GlobeNewswire

Why Science Applications International Shares Are Trading Lower By 11%? Here Are Other Stocks Moving In Monday's Mid-Day Session ↗

June 03, 2024

Via Benzinga

Stericycle, MarineMax, Agios Pharmaceuticals And Other Big Stocks Moving Higher On Monday ↗

June 03, 2024

Via Benzinga

CG Oncology to Present Positive Final Results from Phase 2 CORE-001 Study of Cretostimogene Grenadenorepvec in Combination with Pembrolizumab in BCG-Unresponsive High-Risk NMIBC at ASCO 2024 Annual Meeting

May 24, 2024

54% complete response (CR) rate at 24-month landmark and meets primary endpoint of the phase 2 study

From CG Oncology Inc.

Via GlobeNewswire

CGON Stock Earnings: CG Oncology Misses EPS for Q1 2024 ↗

May 09, 2024

CGON stock results show that CG Oncology missed analyst estimates for earnings per share the first quarter of 2024.

Via InvestorPlace

CG Oncology Reports First Quarter 2024 Financial Results and Provides Business Updates

May 09, 2024

From CG Oncology Inc.

Via GlobeNewswire

12 Health Care Stocks Moving In Friday's Intraday Session ↗

May 03, 2024

Via Benzinga

Cretostimogene Monotherapy Demonstrated 75.2% Complete Response Rate in High-Risk, BCG-Unresponsive Non-Muscle Invasive Bladder Cancer

May 03, 2024

From CG Oncology Inc.

Via GlobeNewswire

Amgen Posts Upbeat Results, Joins OneSpan, Paylocity Holding, MercadoLibre And Other Big Stocks Moving Higher On Friday ↗

May 03, 2024

Via Benzinga

CG Oncology to Host Virtual Investor Event on Friday, May 3, 2024

April 26, 2024

Company to host virtual investor event on Friday, May 3, 2024, at 4:30pm EDT following presentation of results from the Phase 3 BOND-003 trial at the 2024 AUA Annual Meeting

From CG Oncology Inc.

Via GlobeNewswire

CG Oncology to Unveil Encouraging Results on Cretostimogene in Combination with Pembrolizumab at ASCO 2024

April 24, 2024

- Final results of CORE-001 Phase 2 trial of cretostimogene in combination with pembrolizumab for the treatment of BCG-unresponsive NMIBC -

From CG Oncology Inc.

Via GlobeNewswire

IPO Stocks: Will Reddit Unplug The Bulging U.S. IPO Pipeline? ↗

March 28, 2024

A bulging pipeline of IPOs are registered, ready to go, and closely watching Reddit's performance. Here are the concerns.

Via Investor's Business Daily

Topics Initial Public Offering

CG Oncology to Present Results on Cretostimogene at the AUA 2024 Annual Meeting

March 28, 2024

- New 12-month data from the Phase 3 BOND-003 trial to be featured in an oral presentation in the Paradigm-shifting, Practice-changing Clinical Trials in Urology plenary session -

From CG Oncology Inc.

Via GlobeNewswire

CG Oncology Announces First Patient Dosed in PIVOT-006 Phase 3 Clinical Trial of Cretostimogene in Intermediate-risk Non-Muscle Invasive Bladder Cancer

February 27, 2024

From CG Oncology Inc.

Via GlobeNewswire

Everyone's Talking About These 2 Biotech IPO Stocks, But Are They Buys? ↗

February 25, 2024

The market's excited for these stocks, but there's no rush to buy them.

Via The Motley Fool

Topics Initial Public Offering

3 attractive stocks that insiders are buying

February 12, 2024

The insiders are buying these attractive stocks. With a bank, a tech, a penny stock, a dividend payer, and a pharmaceutical winner, there is something for all.

Via MarketBeat

CymaBay Therapeutics, ContextLogic, Snap And Other Big Stocks Moving Higher On Monday ↗

February 12, 2024

U.S. stocks were mixed, with the Nasdaq Composite trading almost flat on Monday. Shares of CymaBay Therapeutics, Inc. (NASDAQ: CBAY) rose sharply in today’s pre-market trading.

Via Benzinga

Topics Stocks

CG Oncology Announces Closing of Initial Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares

January 30, 2024

From CG Oncology, Inc.

Via Business Wire

KKR-Backed BrightSpring Prices Below Expectations, Then Opens Lower ↗

January 28, 2024

Health-care services provider BrightSpring, which is backed by private equity firm KKR, priced its initial public offering at $13, below a marketed range of $15 to $18 per share, before opening on...

Via Talk Markets

Topics Initial Public Offering

KLA Reports Q2 Results, Joins Visa, Western Digital And Other Big Stocks Moving Lower In Friday's Pre-Market Session ↗

January 26, 2024

U.S. stock futures were lower this morning, with the Dow futures falling around 100 points on Friday.

Via Benzinga

Topics Stocks

< Previous 1 2 3 4 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.